Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F19%3A10400345" target="_blank" >RIV/00216208:11140/19:10400345 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14310/19:00113450 RIV/00669806:_____/19:10400345
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=osgd-_ZUQo" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=osgd-_ZUQo</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00066-019-01491-0" target="_blank" >10.1007/s00066-019-01491-0</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences
Popis výsledku v původním jazyce
Purpose This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. Methods Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. Results The mean HR-CTV (high risk-clinical target volume) D-90 was 87 & x202f;+/- 5.1 & x202f;Gy equivalent dose corresponding to the conventional fractionation using 2 & x202f;Gy per fraction (EQD2, range 70.7-97.9 & x202f;Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2 & x202f;cm(rectum)(3)& x202f;= 62.6 & x202f;+/- 6.9 & x202f;Gy EQD2 (range 38.2-77.2 & x202f;Gy), D2 & x202f;cm(sigmoid)(3)& x202f;= 66.2 & x202f;+/- 6.8 & x202f;Gy EQD2 (43.2-78.6 & x202f;Gy) and D2 & x202f;cm(bladder)(3)& x202f;= 75.1 & x202f;+/- 8.3 & x202f;Gy EQD2 (58.2-92.6 & x202f;Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. Conclusion The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.
Název v anglickém jazyce
Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences
Popis výsledku anglicky
Purpose This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. Methods Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. Results The mean HR-CTV (high risk-clinical target volume) D-90 was 87 & x202f;+/- 5.1 & x202f;Gy equivalent dose corresponding to the conventional fractionation using 2 & x202f;Gy per fraction (EQD2, range 70.7-97.9 & x202f;Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2 & x202f;cm(rectum)(3)& x202f;= 62.6 & x202f;+/- 6.9 & x202f;Gy EQD2 (range 38.2-77.2 & x202f;Gy), D2 & x202f;cm(sigmoid)(3)& x202f;= 66.2 & x202f;+/- 6.8 & x202f;Gy EQD2 (43.2-78.6 & x202f;Gy) and D2 & x202f;cm(bladder)(3)& x202f;= 75.1 & x202f;+/- 8.3 & x202f;Gy EQD2 (58.2-92.6 & x202f;Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. Conclusion The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Strahlentherapie und Onkologie
ISSN
0179-7158
e-ISSN
—
Svazek periodika
195
Číslo periodika v rámci svazku
11
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
10
Strana od-do
972-981
Kód UT WoS článku
000494072900003
EID výsledku v databázi Scopus
2-s2.0-85069001370